Connection

Co-Authors

This is a "connection" page, showing publications co-authored by ARA A VAPORCIYAN and DAVID C RICE.
Connection Strength

9.683
  1. SABR vs surgery for NSCLC in the media. Lancet Oncol. 2015 Sep; 16(9):e422.
    View in: PubMed
    Score: 0.524
  2. Conditional Survival of Patients With Early-Stage Non-Small Cell Lung Cancer Who Undergo Lobectomy, Segmentectomy, or Wedge Resection Using the NCDB. J Surg Oncol. 2024 Dec 05.
    View in: PubMed
    Score: 0.249
  3. Enhanced recovery after surgery improves postdischarge recovery after pulmonary lobectomy. J Thorac Cardiovasc Surg. 2023 05; 165(5):1731-1740.e5.
    View in: PubMed
    Score: 0.215
  4. Surgical Complexity of Pulmonary Resections Performed for Oligometastatic NSCLC. JTO Clin Res Rep. 2022 Mar; 3(3):100288.
    View in: PubMed
    Score: 0.205
  5. Matched Pairs Comparison of an Enhanced Recovery Pathway Versus Conventional Management on Opioid Exposure and Pain Control in Patients Undergoing Lung Surgery. Ann Surg. 2021 12 01; 274(6):1099-1106.
    View in: PubMed
    Score: 0.202
  6. Intraoperative Dexmedetomidine and Ketamine Infusions in an Enhanced Recovery After Thoracic Surgery Program: A Propensity Score Matched Analysis. J Cardiothorac Vasc Anesth. 2022 Apr; 36(4):1064-1072.
    View in: PubMed
    Score: 0.200
  7. Robotic Surgery and Anatomic Segmentectomy: An Analysis of Trends, Patient Selection, and Outcomes. Ann Thorac Surg. 2022 03; 113(3):975-983.
    View in: PubMed
    Score: 0.193
  8. Importance of resection for locoregional disease control in Masaoka stage IVA thymic neoplasms. J Surg Oncol. 2020 Sep; 122(3):515-522.
    View in: PubMed
    Score: 0.182
  9. Persistent opioid use is associated with worse survival after lobectomy for stage I non-small cell lung cancer. Pain. 2019 10; 160(10):2365-2373.
    View in: PubMed
    Score: 0.174
  10. Perioperative outcomes among chronic opioid users who receive lobectomy for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2020 02; 159(2):691-702.e5.
    View in: PubMed
    Score: 0.174
  11. Robotic-Assisted Lobectomy for Non-Small Cell Lung Cancer: A Comprehensive Institutional Experience. Ann Thorac Surg. 2019 08; 108(2):370-376.
    View in: PubMed
    Score: 0.168
  12. Enhanced Recovery Decreases Pulmonary and Cardiac Complications After Thoracotomy for Lung Cancer. Ann Thorac Surg. 2018 07; 106(1):272-279.
    View in: PubMed
    Score: 0.156
  13. Salvage pulmonary resection after stereotactic body radiotherapy: A feasible and safe option for local failure in selected patients. J Thorac Cardiovasc Surg. 2017 08; 154(2):689-699.
    View in: PubMed
    Score: 0.147
  14. Predictors of recurrent pulmonary metastases and survival after pulmonary metastasectomy for colorectal cancer. Ann Thorac Surg. 2012 Dec; 94(6):1802-9.
    View in: PubMed
    Score: 0.107
  15. Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy. Ann Oncol. 2013 Jan; 24(1):67-74.
    View in: PubMed
    Score: 0.107
  16. The prognostic factors of chest wall metastasis resection. Eur J Cardiothorac Surg. 2011 Aug; 40(2):328-33.
    View in: PubMed
    Score: 0.097
  17. Progression after chemotherapy is a novel predictor of poor outcomes after pulmonary metastasectomy in sarcoma patients. J Am Coll Surg. 2011 May; 212(5):821-6.
    View in: PubMed
    Score: 0.096
  18. Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer. Cancer. 2011 Jan 01; 117(1):63-9.
    View in: PubMed
    Score: 0.093
  19. Endoscopic ultrasound-guided fine needle aspiration for staging of malignant pleural mesothelioma. Ann Thorac Surg. 2009 Sep; 88(3):862-8; discussion 868-9.
    View in: PubMed
    Score: 0.086
  20. Esophageal tumor length is independently associated with long-term survival. Cancer. 2009 Feb 01; 115(3):508-16.
    View in: PubMed
    Score: 0.083
  21. Comment on "Treatment of non-small cell lung cancer stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)". Chest. 2008 Dec; 134(6):1349.
    View in: PubMed
    Score: 0.082
  22. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007 Nov; 84(5):1685-92; discussion 1692-3.
    View in: PubMed
    Score: 0.076
  23. Sarcomatoid carcinoma of the lung: a predictor of poor prognosis. Ann Thorac Surg. 2007 Sep; 84(3):973-80.
    View in: PubMed
    Score: 0.075
  24. Propensity-matched analysis of three techniques for intrathoracic esophagogastric anastomosis. Ann Thorac Surg. 2007 May; 83(5):1805-13; discussion 1813.
    View in: PubMed
    Score: 0.074
  25. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2007 Oct 01; 69(2):350-7.
    View in: PubMed
    Score: 0.074
  26. Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg. 2005 Dec; 80(6):1988-92; discussion 1992-3.
    View in: PubMed
    Score: 0.067
  27. Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thorac Surg. 2005 Feb; 79(2):391-7; discussionn 391-7.
    View in: PubMed
    Score: 0.063
  28. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2024 Oct 23; 12(10).
    View in: PubMed
    Score: 0.062
  29. Relationship of Surgical Approach With Financial Toxicity in Patients With Resected Lung Cancer. J Surg Oncol. 2024 Sep 10.
    View in: PubMed
    Score: 0.061
  30. Signet ring cells and conditional survival after trimodality therapy for esophageal adenocarcinoma. J Surg Oncol. 2024 Sep; 130(3):428-434.
    View in: PubMed
    Score: 0.061
  31. Pulmonary Surgical Margins for Metastatic Osteosarcoma: Is Negative Margin Enough? Ann Thorac Surg. 2024 Jun 03.
    View in: PubMed
    Score: 0.060
  32. Octreotide's role in the management of post-esophagectomy chylothorax. Dis Esophagus. 2024 Jun 01; 37(6).
    View in: PubMed
    Score: 0.060
  33. Early Interventional Treatment of High Output Chyle Leak After Esophagectomy is Associated With Improved Survival. Ann Surg. 2024 Jul 01; 280(1):91-97.
    View in: PubMed
    Score: 0.059
  34. Risk factors associated with atrial fibrillation after noncardiac thoracic surgery: analysis of 2588 patients. J Thorac Cardiovasc Surg. 2004 Mar; 127(3):779-86.
    View in: PubMed
    Score: 0.059
  35. Do resected colorectal cancer patients need early chest imaging? Impact of clinicopathologic characteristics on time to development of pulmonary metastases. J Surg Oncol. 2024 Feb; 129(2):331-337.
    View in: PubMed
    Score: 0.058
  36. Circulomic variables predict pathologic staging preoperatively in treatment-na?ve non-small cell lung cancer. J Thorac Dis. 2023 Oct 31; 15(10):5507-5516.
    View in: PubMed
    Score: 0.058
  37. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2024 Apr; 167(4):1444-1453.e4.
    View in: PubMed
    Score: 0.057
  38. The risk of second primary tumors after resection of stage I nonsmall cell lung cancer. Ann Thorac Surg. 2003 Oct; 76(4):1001-7; discussion 1007-8.
    View in: PubMed
    Score: 0.057
  39. Factors associated with receipt of pulmonary metastasectomy in patients with lung-limited metastatic colorectal cancer: Disparities in care and impact on overall survival. J Thorac Cardiovasc Surg. 2024 Jul; 168(1):263-271.
    View in: PubMed
    Score: 0.057
  40. Impact of travel distance on receipt of indicated adjuvant therapy in resected non-small cell lung cancer. J Thorac Cardiovasc Surg. 2024 May; 167(5):1617-1627.
    View in: PubMed
    Score: 0.057
  41. Perioperative and oncologic outcomes of pulmonary resection for synchronous oligometastatic non-small cell lung cancer: Evidence for surgery in advanced disease. J Thorac Cardiovasc Surg. 2024 Jun; 167(6):1929-1935.e2.
    View in: PubMed
    Score: 0.057
  42. Radiographic response to neoadjuvant therapy in pleural mesothelioma should serve as a guide for patient selection for cytoreductive operations. Front Oncol. 2023; 13:1216999.
    View in: PubMed
    Score: 0.057
  43. Lung surveillance following colorectal cancer pulmonary metastasectomy: Utilization of clinicopathologic risk factors to guide strategy. J Thorac Cardiovasc Surg. 2024 Mar; 167(3):814-819.e2.
    View in: PubMed
    Score: 0.057
  44. Perspectives, risk factors, and coping mechanisms in patients with self-reported financial burden following lung cancer surgery. J Thorac Cardiovasc Surg. 2024 02; 167(2):478-487.e2.
    View in: PubMed
    Score: 0.056
  45. Financial Toxicity in Patients With Resected Lung Cancer. Ann Surg. 2023 12 01; 278(6):1038-1044.
    View in: PubMed
    Score: 0.056
  46. Disparities in early-stage lung cancer outcomes at minority-serving hospitals compared with nonminority serving hospitals. J Thorac Cardiovasc Surg. 2024 01; 167(1):329-337.e4.
    View in: PubMed
    Score: 0.056
  47. Gastric Extent of Tumor Predicts Peritoneal Metastasis in Siewert II Adenocarcinoma. Ann Thorac Surg. 2024 02; 117(2):320-326.
    View in: PubMed
    Score: 0.056
  48. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 03; 29(3):593-604.
    View in: PubMed
    Score: 0.055
  49. Clinical outcomes of combined cervical and transthoracic surgical approaches in patients with advanced thyroid cancer. Head Neck. 2023 03; 45(3):547-554.
    View in: PubMed
    Score: 0.054
  50. Intraoperative challenges after induction therapy for non-small cell lung cancer: Effect of nodal disease on technical complexity. JTCVS Open. 2022 Dec; 12:372-384.
    View in: PubMed
    Score: 0.054
  51. High-Risk Features of Esophageal Adenocarcinoma Following Neoadjuvant Chemoradiation: Patients for Whom Surgery Should Not Be Delayed. Ann Surg. 2023 05 01; 277(5):721-726.
    View in: PubMed
    Score: 0.053
  52. Repeated Pulmonary Metastasectomy: Third?Operations and Beyond. Ann Thorac Surg. 2023 03; 115(3):679-685.
    View in: PubMed
    Score: 0.053
  53. Resection of advanced thoracic malignancies requiring cardiopulmonary bypass. Eur J Cardiothorac Surg. 2002 Jul; 22(1):47-52.
    View in: PubMed
    Score: 0.053
  54. The Role of Surgery in the Treatment of Melanoma Pulmonary Metastases in the Modern Era. J Surg Res. 2022 09; 277:125-130.
    View in: PubMed
    Score: 0.052
  55. Prolonged neutrophilia is associated with worse outcomes after Esophagectomy. Dis Esophagus. 2022 Apr 19; 35(4).
    View in: PubMed
    Score: 0.052
  56. Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022 11; 164(5):1327-1337.
    View in: PubMed
    Score: 0.051
  57. Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. Lung Cancer. 2022 02; 164:69-75.
    View in: PubMed
    Score: 0.051
  58. Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. Ann Thorac Surg. 2022 12; 114(6):2032-2040.
    View in: PubMed
    Score: 0.051
  59. Barriers to surveillance imaging adherence in early-staged lung cancer. J Thorac Dis. 2021 Dec; 13(12):6848-6854.
    View in: PubMed
    Score: 0.051
  60. Sustained reduction of discharge opioid prescriptions in an enhanced recovery after thoracic surgery program: A multilevel generalized linear model. Surgery. 2022 02; 171(2):504-510.
    View in: PubMed
    Score: 0.050
  61. Analysis of trimodal and bimodal therapy in a selective-surgery paradigm for locally advanced oesophageal squamous cell carcinoma. Br J Surg. 2021 10 23; 108(10):1207-1215.
    View in: PubMed
    Score: 0.050
  62. Clinical Significance of [18F] Fluoro-2-Deoxy-d-Glucose/Computed Tomographic Avid Hilar Lymph Nodes in Esophageal Carcinoma Patients. Ann Thorac Surg. 2022 10; 114(4):1183-1188.
    View in: PubMed
    Score: 0.050
  63. Optimizing Discharge After Shorter Hospitalizations: Lessons Learned Through After-Hours Calls with Thoracic Surgical Patients. Innovations (Phila). 2021 Nov-Dec; 16(6):529-535.
    View in: PubMed
    Score: 0.050
  64. Modern Perioperative Practices May Mitigate Effects of Continued Smoking Among Lung Cancer Patients. Ann Thorac Surg. 2022 07; 114(1):286-292.
    View in: PubMed
    Score: 0.049
  65. Preoperative Maximum Standardized Uptake Value Associated With Recurrence Risk in Early Lung Cancer. Ann Thorac Surg. 2022 06; 113(6):1835-1844.
    View in: PubMed
    Score: 0.049
  66. Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother. 2021 Jul; 70(7):1977-1978.
    View in: PubMed
    Score: 0.049
  67. Pulmonary resection for tissue harvest in adoptive tumor-infiltrating lymphocyte therapy: Safety and feasibility. J Surg Oncol. 2021 Sep; 124(4):699-703.
    View in: PubMed
    Score: 0.049
  68. Extrapleural Pneumonectomy Versus Pleurectomy/Decortication for Malignant Pleural Mesothelioma. Ann Thorac Surg. 2022 01; 113(1):200-208.
    View in: PubMed
    Score: 0.049
  69. Impact of Psychiatric Comorbidities on Surgical Outcomes for Non-Small Cell Lung?Cancer. Ann Thorac Surg. 2022 03; 113(3):1008-1014.
    View in: PubMed
    Score: 0.048
  70. Simultaneous versus staged resections for bilateral pulmonary metastases. J Surg Oncol. 2021 Jun; 123(7):1633-1639.
    View in: PubMed
    Score: 0.048
  71. Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues. Sci Rep. 2021 02 25; 11(1):4530.
    View in: PubMed
    Score: 0.048
  72. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
    View in: PubMed
    Score: 0.048
  73. Intestinal Metaplasia in the Esophageal Remnant Is Rare After Ivor Lewis Esophagectomy. J Gastrointest Surg. 2021 09; 25(9):2185-2191.
    View in: PubMed
    Score: 0.048
  74. CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother. 2021 Jul; 70(7):1965-1976.
    View in: PubMed
    Score: 0.047
  75. Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. Eur J Cardiothorac Surg. 2021 01 04; 59(1):100-108.
    View in: PubMed
    Score: 0.047
  76. Liposomal Bupivacaine Intercostal Block Is Important for Reduction of Pulmonary Complications. Ann Thorac Surg. 2021 08; 112(2):423-429.
    View in: PubMed
    Score: 0.047
  77. Postoperative Bleeding and Acute Kidney Injury in Esophageal Cancer Patients Receiving Ketorolac. Ann Thorac Surg. 2021 04; 111(4):1111-1117.
    View in: PubMed
    Score: 0.047
  78. Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. J Thorac Cardiovasc Surg. 2021 Nov; 162(5):1404-1412.e2.
    View in: PubMed
    Score: 0.046
  79. Modified En Bloc Esophagectomy Compared With Standard Resection After Neoadjuvant Chemoradiation. Ann Thorac Surg. 2021 04; 111(4):1133-1140.
    View in: PubMed
    Score: 0.046
  80. Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. Lung Cancer. 2020 08; 146:303-309.
    View in: PubMed
    Score: 0.046
  81. Time trends and predictors of survival in surgically resected early-stage non-small cell lung cancer patients. J Surg Oncol. 2020 Sep; 122(3):495-505.
    View in: PubMed
    Score: 0.045
  82. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 07 15; 26(14):3525-3536.
    View in: PubMed
    Score: 0.045
  83. Morbidity following salvage esophagectomy for squamous cell carcinoma: the MD Anderson experience. Dis Esophagus. 2020 Mar 16; 33(3).
    View in: PubMed
    Score: 0.045
  84. Hospital readmissions after pulmonary resection: post-discharge nursing telephone assessment identifies high risk patients. J Thorac Dis. 2020 Mar; 12(3):184-190.
    View in: PubMed
    Score: 0.045
  85. Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities. J Thorac Dis. 2020 Mar; 12(3):329-337.
    View in: PubMed
    Score: 0.045
  86. High mutational concordance between primary colorectal tumors and associated pulmonary metastases. J Surg Oncol. 2020 May; 121(6):984-989.
    View in: PubMed
    Score: 0.045
  87. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clin Lung Cancer. 2020 07; 21(4):e294-e301.
    View in: PubMed
    Score: 0.044
  88. Surveillance After Treatment of Non-Small-Cell Lung Cancer: A Call for Multidisciplinary Standardization. Innovations (Phila). 2020 Jan/Feb; 15(1):57-65.
    View in: PubMed
    Score: 0.044
  89. Preoperative Heparin for Lung Cancer Resection Increases Risk of Reoperation for Bleeding. Semin Thorac Cardiovasc Surg. 2020 Summer; 32(2):337-343.
    View in: PubMed
    Score: 0.044
  90. Should endoscopic mucosal resection be attempted for cT2N0 esophageal cancer? Dis Esophagus. 2019 Dec 13; 32(10):1-6.
    View in: PubMed
    Score: 0.044
  91. Time Trends of Perioperative Outcomes in Early Stage Non-Small Cell Lung Cancer Resection Patients. Ann Thorac Surg. 2020 02; 109(2):404-411.
    View in: PubMed
    Score: 0.043
  92. Multidisciplinary treatment of thymic neuroendocrine tumors: surgery remains a key component. J Thorac Dis. 2019 Aug; 11(8):3391-3398.
    View in: PubMed
    Score: 0.043
  93. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice. Cancer. 2019 11 01; 125(21):3738-3748.
    View in: PubMed
    Score: 0.043
  94. Colorectal cancer mutations are associated with survival and recurrence after pulmonary metastasectomy. J Surg Oncol. 2019 Sep; 120(4):729-735.
    View in: PubMed
    Score: 0.043
  95. Glutathione reductase (GSR) gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization. Am J Cancer Res. 2019; 9(6):1201-1211.
    View in: PubMed
    Score: 0.042
  96. Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma. Ann Thorac Surg. 2019 09; 108(3):845-851.
    View in: PubMed
    Score: 0.042
  97. Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database. J Thorac Dis. 2019 Apr; 11(4):1269-1278.
    View in: PubMed
    Score: 0.042
  98. Occult stage IIIA-N2 patients have excellent overall survival with initial surgery. J Thorac Dis. 2018 Dec; 10(12):6670-6676.
    View in: PubMed
    Score: 0.041
  99. Local Recurrence After Microwave Ablation of Lung Malignancies: A Systematic Review. Ann Thorac Surg. 2019 06; 107(6):1876-1883.
    View in: PubMed
    Score: 0.041
  100. Surgical margins and risk of local recurrence after wedge resection of colorectal pulmonary metastases. J Thorac Cardiovasc Surg. 2019 04; 157(4):1648-1655.
    View in: PubMed
    Score: 0.041
  101. Ground Glass Lesions on Chest Imaging: Evaluation of Reported Incidence in Cancer Patients Using Natural Language Processing. Ann Thorac Surg. 2019 03; 107(3):936-940.
    View in: PubMed
    Score: 0.041
  102. Predictors of survival after resection of primary sarcomas of the chest wall-A large, single-institution series. J Surg Oncol. 2018 Sep; 118(3):518-524.
    View in: PubMed
    Score: 0.040
  103. Perioperative Outcomes for Stage I Non-Small Cell Lung Cancer: Differences Between Men and Women. Ann Thorac Surg. 2018 11; 106(5):1499-1503.
    View in: PubMed
    Score: 0.040
  104. Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2018 05 01; 53(5):960-966.
    View in: PubMed
    Score: 0.039
  105. Outcomes after endoscopic mucosal resection or esophagectomy for submucosal esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2018 07; 156(1):406-413.e3.
    View in: PubMed
    Score: 0.039
  106. Clinicoradiographic Predictors of Aggressive Biology in Lung Cancer With Ground Glass Components. Ann Thorac Surg. 2018 07; 106(1):235-241.
    View in: PubMed
    Score: 0.039
  107. Genetic variants in cytokine signaling pathways and clinical outcomes in early-stage lung cancer patients. J Thorac Cardiovasc Surg. 2018 06; 155(6):2635-2645.e15.
    View in: PubMed
    Score: 0.039
  108. Natural History of Ground-Glass Lesions Among Patients With Previous Lung Cancer. Ann Thorac Surg. 2018 06; 105(6):1671-1677.
    View in: PubMed
    Score: 0.039
  109. Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. Cancer. 2018 03 01; 124(5):1061-1069.
    View in: PubMed
    Score: 0.038
  110. Perioperative Outcomes of Patients Undergoing Lobectomy on Clopidogrel. Ann Thorac Surg. 2017 Dec; 104(6):1821-1828.
    View in: PubMed
    Score: 0.038
  111. Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis. J Clin Oncol. 2017 Oct 10; 35(29):3354-3362.
    View in: PubMed
    Score: 0.038
  112. Polytetrafluoroethylene or Acellular Dermal Matrix for Diaphragmatic Reconstruction? Ann Thorac Surg. 2017 Jun; 103(6):1710-1714.
    View in: PubMed
    Score: 0.037
  113. Outcomes of chest wall resections in pediatric sarcoma patients. J Pediatr Surg. 2017 Jan; 52(1):109-114.
    View in: PubMed
    Score: 0.035
  114. Stage I lung cancer-to operate or to radiate? that is the question. J Thorac Dis. 2016 Sep; 8(9):2324-2327.
    View in: PubMed
    Score: 0.035
  115. The Influence of Reconstructive Technique on Perioperative Pulmonary and Infectious Outcomes Following Chest Wall Resection. Ann Thorac Surg. 2016 Nov; 102(5):1653-1659.
    View in: PubMed
    Score: 0.035
  116. Patient-Reported Symptom Interference as a Measure of Postsurgery Functional Recovery in Lung Cancer. J Pain Symptom Manage. 2016 12; 52(6):822-831.
    View in: PubMed
    Score: 0.035
  117. Results of Postdischarge Nursing Telephone Assessments: Persistent Symptoms Common Among Pulmonary Resection Patients. Ann Thorac Surg. 2016 Jul; 102(1):276-81.
    View in: PubMed
    Score: 0.034
  118. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. Ann Thorac Surg. 2016 Mar; 101(3):1075-80; Discussion 1080-1.
    View in: PubMed
    Score: 0.033
  119. Clinical Prediction of Pathologic Complete Response in Superior Sulcus Non-Small Cell Lung Cancer. Ann Thorac Surg. 2016 Jan; 101(1):211-7.
    View in: PubMed
    Score: 0.033
  120. Symptom recovery after thoracic surgery: Measuring patient-reported outcomes with the MD Anderson Symptom Inventory. J Thorac Cardiovasc Surg. 2015 Sep; 150(3):613-9.e2.
    View in: PubMed
    Score: 0.032
  121. Limitations of 18F-2-deoxy-D-glucose positron emission tomography in N1 detection in patients with pathologic stage II-N1 and implications for management. Ann Thorac Surg. 2015 Feb; 99(2):414-20.
    View in: PubMed
    Score: 0.031
  122. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett. 2015 Feb 01; 357(1):179-185.
    View in: PubMed
    Score: 0.031
  123. Thoracoscopic lobectomy is associated with improved short-term and equivalent oncological outcomes compared with open lobectomy for clinical Stage I non-small-cell lung cancer: a propensity-matched analysis of 963 cases. Eur J Cardiothorac Surg. 2014 Oct; 46(4):607-13.
    View in: PubMed
    Score: 0.030
  124. The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma. Ann Surg. 2013 Sep; 258(3):500-7.
    View in: PubMed
    Score: 0.029
  125. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2013 Nov; 24(11):2844-9.
    View in: PubMed
    Score: 0.028
  126. Diaphragmatic hernia after esophagectomy in 440 patients with long-term follow-up. Ann Thorac Surg. 2013 Oct; 96(4):1138-1145.
    View in: PubMed
    Score: 0.028
  127. Visceral pleural invasion is not predictive of survival in patients with lung cancer and smaller tumor size. Ann Thorac Surg. 2013 Jun; 95(6):1872-7; discussion 1877.
    View in: PubMed
    Score: 0.028
  128. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol. 2013 May; 24(5):1262-6.
    View in: PubMed
    Score: 0.027
  129. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology. 2012; 83(5):300-4.
    View in: PubMed
    Score: 0.027
  130. Supercharged pedicled jejunal interposition for esophageal replacement: a 10-year experience. Ann Thorac Surg. 2012 Oct; 94(4):1104-11; discussion 1111-3.
    View in: PubMed
    Score: 0.027
  131. Omental reinforcement of the thoracic esophagogastric anastomosis: an analysis of leak and reintervention rates in patients undergoing planned and salvage esophagectomy. J Thorac Cardiovasc Surg. 2012 Nov; 144(5):1146-50.
    View in: PubMed
    Score: 0.027
  132. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma. Ann Thorac Surg. 2012 Oct; 94(4):1126-32; discussion 1132-3.
    View in: PubMed
    Score: 0.027
  133. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2012 Oct; 23(10):2638-2642.
    View in: PubMed
    Score: 0.026
  134. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg. 2012 Sep; 94(3):914-20.
    View in: PubMed
    Score: 0.026
  135. Contemporary surgical management of cardiac paragangliomas. Ann Thorac Surg. 2012 Jun; 93(6):1972-6.
    View in: PubMed
    Score: 0.026
  136. Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial margins. J Thorac Cardiovasc Surg. 2012 Feb; 143(2):412-20.
    View in: PubMed
    Score: 0.025
  137. Patients with high body mass index tend to have lower stage of esophageal carcinoma at diagnosis. Dis Esophagus. 2012 Sep-Oct; 25(7):614-22.
    View in: PubMed
    Score: 0.025
  138. Does the timing of esophagectomy after chemoradiation affect outcome? Ann Thorac Surg. 2012 Jan; 93(1):207-12; discussion 212-3.
    View in: PubMed
    Score: 0.025
  139. Outcomes after right-side heart sarcoma resection. Ann Thorac Surg. 2011 Mar; 91(3):770-6.
    View in: PubMed
    Score: 0.024
  140. The influence of high body mass index on the prognosis of patients with esophageal cancer after surgery as primary therapy. Cancer. 2010 Dec 15; 116(24):5619-27.
    View in: PubMed
    Score: 0.023
  141. Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. Cancer. 2011 Mar 01; 117(5):925-30.
    View in: PubMed
    Score: 0.023
  142. Minimally invasive esophagectomy versus open esophagectomy, a symptom assessment study. Dis Esophagus. 2011 Apr; 24(3):147-52.
    View in: PubMed
    Score: 0.023
  143. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg. 2010 Sep; 90(3):884-90; discussion 890-1.
    View in: PubMed
    Score: 0.023
  144. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg. 2010 Sep; 90(3):892-8; discussion 898-9.
    View in: PubMed
    Score: 0.023
  145. Non-small cell lung cancer resection in lymphoma patients. Ann Thorac Surg. 2010 Jul; 90(1):210-6.
    View in: PubMed
    Score: 0.023
  146. Comparison between established and the Worldwide Esophageal Cancer Collaboration staging systems. Ann Thorac Surg. 2010 Jun; 89(6):1797-1803, 1804.e1-3; discussion 1803-4.
    View in: PubMed
    Score: 0.023
  147. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer. 2010 Apr 01; 116(7):1656-63.
    View in: PubMed
    Score: 0.023
  148. Association of age and survival in patients with gastroesophageal cancer undergoing surgery with or without preoperative therapy. Cancer. 2009 Oct 01; 115(19):4450-8.
    View in: PubMed
    Score: 0.022
  149. Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. Ann Thorac Surg. 2009 Sep; 88(3):877-84; discussion 884-5.
    View in: PubMed
    Score: 0.022
  150. Influence of age on choice of therapy and surgical outcomes in patients with nonsmall cell lung cancer. Am Surg. 2009 Jul; 75(7):598-603; discussion 603-4.
    View in: PubMed
    Score: 0.021
  151. Superior sulcus tumors with vertebral body involvement: a multimodality approach. J Thorac Cardiovasc Surg. 2009 Jun; 137(6):1379-87.
    View in: PubMed
    Score: 0.021
  152. Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population. J Thorac Cardiovasc Surg. 2009 Aug; 138(2):412-418.e1-2.
    View in: PubMed
    Score: 0.021
  153. Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2009 Oct; 138(4):831-6.
    View in: PubMed
    Score: 0.021
  154. Outcomes after surgical resection of cardiac sarcoma in the multimodality treatment era. J Thorac Cardiovasc Surg. 2009 Jun; 137(6):1454-60.
    View in: PubMed
    Score: 0.021
  155. Management of primary pulmonary artery sarcomas. Ann Thorac Surg. 2009 Mar; 87(3):977-84.
    View in: PubMed
    Score: 0.021
  156. 3p22.1 and 10q22.3 deletions detected by fluorescence in situ hybridization (FISH): a potential new tool for early detection of non-small cell lung Cancer (NSCLC). J Thorac Oncol. 2008 Sep; 3(9):979-84.
    View in: PubMed
    Score: 0.020
  157. Cardiac autotransplantation for malignant or complex primary left-heart tumors. Tex Heart Inst J. 2008; 35(3):296-300.
    View in: PubMed
    Score: 0.019
  158. Comparison of limited surgery and three-dimensional conformal radiation in high-risk patients with stage I non-small cell lung cancer. J Thorac Oncol. 2007 Nov; 2(11):1022-8.
    View in: PubMed
    Score: 0.019
  159. Use of aprotinin in extrapleural pneumonectomy: effect on hemostasis and incidence of complications. Ann Thorac Surg. 2007 Sep; 84(3):982-6.
    View in: PubMed
    Score: 0.019
  160. Proposed modification of nodal status in AJCC esophageal cancer staging system. Ann Thorac Surg. 2007 Aug; 84(2):365-73; discussion 374-5.
    View in: PubMed
    Score: 0.019
  161. Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. Ann Surg Oncol. 2007 Jul; 14(7):2010-7.
    View in: PubMed
    Score: 0.018
  162. Increased risk of aspiration and pulmonary complications after lung resection in head and neck cancer patients. Ann Thorac Surg. 2006 Dec; 82(6):1982-7; discussion 1987-8.
    View in: PubMed
    Score: 0.018
  163. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer. 2006 Sep 01; 107(5):967-74.
    View in: PubMed
    Score: 0.018
  164. Cardiac autotransplantation for primary cardiac tumors. Ann Thorac Surg. 2006 Aug; 82(2):645-50.
    View in: PubMed
    Score: 0.017
  165. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer. 2006 Feb 01; 106(3):552-8.
    View in: PubMed
    Score: 0.017
  166. Gender-based analysis of esophageal cancer patients undergoing preoperative chemoradiation: differences in presentation and therapy outcome. Dis Esophagus. 2006; 19(3):152-7.
    View in: PubMed
    Score: 0.017
  167. Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2006 Jan; 131(1):65-72.
    View in: PubMed
    Score: 0.017
  168. The evolution of treatment outcomes for resected stage IIIA non-small cell lung cancer over 16 years at a single institution. J Thorac Cardiovasc Surg. 2005 Dec; 130(6):1601-10.
    View in: PubMed
    Score: 0.017
  169. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005 Dec 01; 104(11):2365-72.
    View in: PubMed
    Score: 0.017
  170. Long-segment, supercharged, pedicled jejunal flap for total esophageal reconstruction. J Thorac Cardiovasc Surg. 2005 Nov; 130(5):1391-8.
    View in: PubMed
    Score: 0.017
  171. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer. 2005 Oct 01; 104(7):1349-55.
    View in: PubMed
    Score: 0.016
  172. Intrathoracic leaks following esophagectomy are no longer associated with increased mortality. Ann Surg. 2005 Sep; 242(3):392-9; discussion 399-402.
    View in: PubMed
    Score: 0.016
  173. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. J Thorac Cardiovasc Surg. 2005 Jun; 129(6):1364-70.
    View in: PubMed
    Score: 0.016
  174. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005 May; 241(5):810-7; discussion 817-20.
    View in: PubMed
    Score: 0.016
  175. Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus. Int J Gastrointest Cancer. 2005; 36(2):69-76.
    View in: PubMed
    Score: 0.016
  176. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004 Oct 15; 101(8):1776-85.
    View in: PubMed
    Score: 0.015
  177. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004 Oct; 78(4):1152-60; discussion 1152-60.
    View in: PubMed
    Score: 0.015
  178. Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol. 2004 Jul; 99(7):1258-66.
    View in: PubMed
    Score: 0.015
  179. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J. 2003 Nov-Dec; 9(6):476-84.
    View in: PubMed
    Score: 0.014
  180. Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology (Williston Park). 2003 Sep; 17(9 Suppl 8):20-2.
    View in: PubMed
    Score: 0.014
  181. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002 Sep; 236(3):376-84; discussion 384-5.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.